{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:59:23Z","timestamp":1758045563713,"version":"3.44.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.amjsurg.2013.04.004","type":"journal-article","created":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T22:12:52Z","timestamp":1381875172000},"page":"95-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antiplatelet and anticoagulation medications and the surgical patient"],"prefix":"10.1016","volume":"207","author":[{"given":"Brian K.","family":"Yorkgitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Ruggia-Check","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay E.","family":"Dujon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjsurg.2013.04.004_bib1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.2146\/ajhp110418","article-title":"Apixaban: a novel oral inhibitor of factor Xa","volume":"69","author":"Nutescu","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib2","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood-2012-06-415943","article-title":"How I treat anticoagulated patients undergoing elective procedures or surgery","volume":"120","author":"Spyropoulos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/AAP.0b013e3181c15c70","article-title":"Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy","volume":"35","author":"Horlocker","year":"2010","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib4","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib5","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guideline","volume":"141","author":"Guyett","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thorsurg.2011.09.007","article-title":"The management of anticoagulants perioperatively","volume":"22","author":"Cerfolio","year":"2012","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib7","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1038\/sj.thj.6200446","article-title":"Antiplatelet agents","volume":"5","author":"Cattaneo","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11886-012-0273-y","article-title":"Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?","volume":"14","author":"Varenhorst","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib10","unstructured":"Effient [Highlights of Prescribing Information] Eli Lilly. Indianapolis, IN; September 2011. Available at: http:\/\/pi.lilly.com\/us\/effient.pdf. Accessed June 3, 2012."},{"key":"10.1016\/j.amjsurg.2013.04.004_bib11","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib12","unstructured":"Brilinta [Highlights of Prescribing Information]. AstraZeneca. Wilmington, DE; July 2007. Available at: http:\/\/www1.astrazeneca-us.com\/pi\/brilinta.pdf. Accessed June 3, 2012."},{"key":"10.1016\/j.amjsurg.2013.04.004_bib13","unstructured":"Pletal [Highlights of Prescribing Information]. Otsuka America Pharmaceutical, Inc., Rockville, MD; May 2007. Available at: http:\/\/www.otsuka-us.com\/Products\/Documents\/PletalPI.2007.pdf. Accessed September 26, 2012."},{"key":"10.1016\/j.amjsurg.2013.04.004_bib14","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.anclin.2010.08.013","article-title":"Anticoagulants: newer ones, mechanisms, and perioperative updates","volume":"28","author":"Gayle","year":"2010","journal-title":"Anesthesiol Clin"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib15","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0002-9149(03)00012-2","article-title":"Bleeding risk of platelet glycoprotein IIb\/IIIa receptor antagonists in broad-based practice (results from the Society for Cardiac Angiography and Interventions Registry)","volume":"91","author":"Horwitz","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib16","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"107","author":"Hirsh","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib17","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1538-7836.2011.04432.x","article-title":"Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents","volume":"9","author":"Levi","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5811\/westjem.2011.3.2051","article-title":"Reversal of warfarin-induced hemorrhage in the emergency department","volume":"12","author":"Zareh","year":"2011","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/clc.22037","article-title":"Emergency management of bleeding associated with old and new oral anticoagulants","volume":"35","author":"Peacock","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib20","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib21","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2007-10-120543","article-title":"Bleeding risk and management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents","volume":"111","author":"Crowther","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib22","unstructured":"Xarelto [Highlights of Prescribing Information]. Janssen Pharmaceuticals, Inc. Titusville, NJ; November 2012. Available at: www.xareltohcp.com\/prescribing-information.pdf. Accessed February 16, 2013."},{"key":"10.1016\/j.amjsurg.2013.04.004_bib23","unstructured":"Eliquis [Highlights of Prescribing Information]. Bristol-Meyers Squibb. Princeton, NJ; December 2012. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf. Accessed February 5, 2013."},{"key":"10.1016\/j.amjsurg.2013.04.004_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib26","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib27","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1472-8206.2011.00981.x","article-title":"Pharmacodynamic and pharmacokinetic basics of rivaroxaban","volume":"26","author":"Kreutz","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor Xa inhibitor","volume":"30","author":"Pezborn","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ccm.2010.06.006","article-title":"New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors","volume":"31","author":"Morris","year":"2010","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","article-title":"Acute management of bleeding in patients on novel oral anticoagulants","volume":"34","author":"Siegal","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ccl.2007.12.005","article-title":"New anticoagulant agents: direct thrombin inhibitors","volume":"26","author":"Nutescu","year":"2008","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib33","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1378\/chest.08-2830","article-title":"Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management","volume":"135","author":"Shantsila","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib34","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1160\/TH07-10-0644","volume":"99","author":"Warkentin","year":"2008","journal-title":"Bivalirudin. Thromb Haemost"},{"key":"10.1016\/j.amjsurg.2013.04.004_bib35","unstructured":"Pradaxa [Highlights of Prescribing Information]. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT; December 2012. Available at: http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf. Accessed January 10, 2013."},{"key":"10.1016\/j.amjsurg.2013.04.004_bib36","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961013004145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961013004145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:02:43Z","timestamp":1757700163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961013004145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0002961013004145"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2013.04.004","relation":{},"ISSN":["0002-9610"],"issn-type":[{"type":"print","value":"0002-9610"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet and anticoagulation medications and the surgical patient","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2013.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}